Estimation of Infection Force of Hepatitis C Virus Among Drug Users in France

被引:6
|
作者
Kasereka, Selain [1 ]
Le Strat, Yann [2 ]
Leon, Lucie [2 ]
机构
[1] Univ Kinshasa, Kinshasa, DEM REP CONGO
[2] French Natl Publ Hlth Agcy, Sante Publ France, St Maurice, Ile De France, France
来源
RECENT ADVANCES IN NONLINEAR DYNAMICS AND SYNCHRONIZATION: WITH SELECTED APPLICATIONS IN ELECTRICAL ENGINEERING, NEUROCOMPUTING, AND TRANSPORTATION | 2018年 / 109卷
关键词
INJECT DRUGS; PEOPLE; PREVENTION; AUSTRALIA; MORTALITY;
D O I
10.1007/978-3-319-58996-1_15
中图分类号
TM [电工技术]; TN [电子技术、通信技术];
学科分类号
0808 ; 0809 ;
摘要
The spread of diseases is a dynamic and complex phenomenon. In the world, they are due to misery and poverty. To understand epidemiological systems is essential for governments. Since modeling simplifies reality, it is an excellent method. The hepatitis C virus (HCV) infection is common worldwide, and injection drug use remains the major mode of transmission of the disease, especially because of equipment sharing. Consequently, it is crucial to monitor the HCV transmission dynamics over time and to assess the effect of harm reduction measures. The aim of this work is to estimate the force of infection of hepatitis C from two national cross-sectional epidemiological surveys conducted in 2004 and 2011 by the French Institute for Public Health Surveillance and its partners in a drug user population in France. HCV prevalence was estimated according to age and calendar time through fractional polynomials adjusted or not to the HIV serological status and to injected drug users or oral drug users in general. The force of infection was modeled according to an SIS (susceptible-infected-susceptible) compartmental model using ordinary differential equations (ODE) and as a function of the derivative of the prevalence function depending on age, time, HIV serological status, and having injected at least once in their life, from 2000 to 2020. Our model was applied on real and simulated surveys using R and Stata software. The results show that HCV prevalence and the force of infection are linked to age and time, and are very high for drug users who injected at least once in their life and who are simultaneously HCV and HIV infected. Based on this model, we estimated that HCV incidence will continue to decline over the following years. Currently in France, there is no cohort study of the HCV among drug users. The only way to estimate HCV incidence in the French population is to use the only existing two national cross-sectional surveys. Our work provides guidance for researchers to compare several cross-sectional epidemiological surveys among drug users and proposes an alternative method to estimate the force of infection among drug users from cross-sectional surveys in the absence of a cohort.
引用
收藏
页码:319 / 344
页数:26
相关论文
共 50 条
  • [21] Prevention of Hepatitis C Virus in Injecting Drug Users: A Narrow Window of Opportunity
    Grebely, Jason
    Dore, Gregory J.
    JOURNAL OF INFECTIOUS DISEASES, 2011, 203 (05) : 571 - 574
  • [22] Taxonomy of Mathematical Modeling Studies for Hepatitis C Among Injection Drug Users
    Yaylali, Emine
    Ucler, Sahincan
    INDUSTRIAL ENGINEERING IN THE INTERNET-OF-THINGS WORLD, GJCIE 2020, 2022, : 477 - 494
  • [23] Hepatitis C related mortality in a cohort of drug users in Flanders
    De Ryck, Henri
    Mathei, Catharina
    HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS, 2020, 22 (03) : 5 - 11
  • [24] Risk of hepatitis C virus infection in injecting and noninjecting drug users receiving opioid substitution therapy
    Wang, Chih-Wen
    Chuang, Hung-Yi
    Chiang, Hung-Che
    Huang, Po-Chin
    Yu, Ming-Lung
    Dai, Chia-Yen
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (05) : 454 - 460
  • [25] Hepatitis C knowledge among new injection drug users
    Jost, John J.
    Goldsamt, Lloyd A.
    Harocopos, Alex
    Kobrak, Paul
    Clatts, Michael C.
    DRUGS-EDUCATION PREVENTION AND POLICY, 2010, 17 (06) : 821 - 834
  • [26] Hepatitis C virus infection: accessing drug treatment
    Smyth, Dan
    Webster, Duncan
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2015, 187 (15) : 1113 - 1114
  • [27] Hepatitis B virus infection among illegal drug users in Enugu State, Nigeria: prevalence, immune status, and related risk factors
    Orabueze, Ibuchukwu N.
    Ike, Anthony C.
    Aniche, Oluchi M.
    Nwafia, Ifeyinwa N.
    Ebede, Samuel O.
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [28] Treatment costs of hepatitis C infection among injection drug users in Canada, 2006-2026
    Werb, Daniel
    Wood, Evan
    Kerr, Thomas
    Hershfield, Neil
    Palmer, Robert W. H.
    Remis, Robert S.
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2011, 22 (01) : 70 - 76
  • [29] The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users
    Nolan, Seonaid
    Lima, Viviane Dias
    Fairbairn, Nadia
    Kerr, Thomas
    Montaner, Julio
    Grebely, Jason
    Wood, Evan
    ADDICTION, 2014, 109 (12) : 2053 - 2059
  • [30] Co-Infection Burden of Hepatitis C Virus and Human Immunodeficiency Virus among Injecting Heroin Users at the Kenyan Coast
    Mwatelah, Ruth S.
    Lwembe, Raphael M.
    Osman, Saida
    Ogutu, Bernhards R.
    Aman, Rashid
    Kitawi, Rose C.
    Wangai, Laura N.
    Oloo, Florence A.
    Kokwaro, Gilbert O.
    Ochieng, Washingtone
    PLOS ONE, 2015, 10 (07):